Shares of Nuformix plc (LON:NFX – Get Free Report) rose 5.5% during trading on Friday . The company traded as high as GBX 0.18 and last traded at GBX 0.17. Approximately 322,418 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 35,481,805 shares. The stock had previously closed at GBX 0.17.
Nuformix Price Performance
The business has a 50 day moving average of GBX 0.18 and a 200 day moving average of GBX 0.23. The company has a market cap of £4.70 million, a PE ratio of -4.58 and a beta of 1.55.
Nuformix (LON:NFX – Get Free Report) last announced its quarterly earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
